Actively Recruiting
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Led by The General Hospital of Western Theater Command · Updated on 2026-03-25
45
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
CONDITIONS
Official Title
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient signed informed consent and voluntarily agreed to participate
- Undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) score between 0 and 2
- Expected survival of at least 3 months
- No severe impairment of major organ function
You will not qualify if you...
- Known allergy to thrombopoietin receptor agonists (TPO-RAs)
- Unable to take oral medication due to gastrointestinal symptoms, altered mental status, or similar reasons during transplantation
- Other exclusion reasons as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The General Hospital of the People's Liberation Army
Chengdu, China
Actively Recruiting
Research Team
L
Lei Ma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here